$AVGR
Avinger Inc Stock $avgr

$avgr Overview Financials Valuation SEC Filings Company Website

2019 Q2 Form 10-Q Financial Statement

#000143774919016045 Filed on August 08, 2019

Income Statement

Concept	2019 Q2	2018 Q2	2018 Q1
Revenue	$2.319M	$2.058M	$1.809M
YoY Change	12.68%	-16.34%	-48.17%
Cost Of Revenue	$1.599M	$2.169M	$1.415M
YoY Change	-26.28%	-44.67%	-65.32%
Gross Profit	$720.0K	-$111.0K	$394.0K
YoY Change	-748.65%	-92.4%	-167.93%
Gross Profit Margin	31.05%	-5.39%	21.78%
Selling, General & Admin	$4.091M	$4.444M	$4.500M
YoY Change	-7.94%	-28.21%	-51.72%
% of Gross Profit	568.19%		1142.13%
Research & Development	$1.335M	$1.159M	$1.777M
YoY Change	15.19%	-62.61%	-54.67%
% of Gross Profit	185.42%		451.02%
Depreciation & Amortization	$230.0K	$240.0K	$277.0K
YoY Change	-4.17%	-42.86%	-35.58%
% of Gross Profit	31.94%		70.3%
Operating Expenses	$5.426M	$5.603M	$6.277M
YoY Change	-3.16%	-39.62%	-52.59%
Operating Profit	-$4.706M	-$5.714M	-$5.883M
YoY Change	-17.64%	-46.8%	-57.43%
Interest Expense	$364.0K	$362.0K	$4.672M
YoY Change	0.55%	-123.66%	-407.37%
% of Operating Profit
Other Income/Expense, Net	$329.0K	$227.0K	$241.0K
YoY Change	44.93%
Pretax Income	-$4.650M	-$5.800M	-$10.28M
YoY Change	-19.83%	-54.69%	-32.99%
Income Tax
% Of Pretax Income
Net Earnings	-$4.651M	-$5.799M	-$10.28M
YoY Change	-19.8%	-54.7%	-32.98%
Net Earnings / Revenue	-200.56%	-281.78%	-568.33%
Basic Earnings Per Share
Diluted Earnings Per Share	-$728.8K	-$8.529M	-$51.40M
COMMON SHARES
Basic Shares Outstanding	64.20M
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q2	2018 Q2	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$14.75M	$10.14M	$14.42M
YoY Change	45.46%	-27.36%	-37.39%
Cash & Equivalents	$14.75M	$10.14M	$14.42M
Short-Term Investments
Other Short-Term Assets	$760.0K	$1.080M	$1.160M
YoY Change	-29.63%	-4.42%	-14.71%
Inventory	$4.105M	$3.650M	$4.010M
Prepaid Expenses
Receivables	$1.210M	$1.680M	$1.350M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$20.83M	$16.55M	$20.94M
YoY Change	25.88%	-28.91%	-39.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.006M	$2.100M	$2.430M
YoY Change	-4.48%	-45.6%	-41.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$384.0K	$580.0K	$590.0K
YoY Change	-33.79%	132.0%	180.95%
Total Long-Term Assets	$7.986M	$2.680M	$3.020M
YoY Change	197.99%	-34.79%	-31.21%
TOTAL ASSETS
Total Short-Term Assets	$20.83M	$16.55M	$20.94M
Total Long-Term Assets	$7.986M	$2.680M	$3.020M
Total Assets	$28.82M	$19.23M	$23.96M
YoY Change	49.86%	-29.79%	-38.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.086M	$1.370M	$2.160M
YoY Change	-20.73%	19.13%	86.21%
Accrued Expenses	$776.0K	$2.010M	$1.860M
YoY Change	-61.39%	-53.47%	-64.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$8.200M	$7.820M	$7.520M
YoY Change	4.86%	-81.6%	-82.04%
Total Short-Term Liabilities	$14.36M	$12.45M	$11.95M
YoY Change	15.3%	-74.04%	-75.25%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$11.00K	$190.0K	$110.0K
YoY Change	-94.21%	-13.64%	-57.69%
Total Long-Term Liabilities	$11.00K	$190.0K	$110.0K
YoY Change	-94.21%	-13.64%	-57.69%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.36M	$12.45M	$11.95M
Total Long-Term Liabilities	$11.00K	$190.0K	$110.0K
Total Liabilities	$18.90M	$12.64M	$12.06M
YoY Change	49.52%	-73.77%	-75.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$338.6M
YoY Change
Common Stock	$348.5M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.920M	$6.592M	$11.90M
YoY Change
Total Liabilities & Shareholders Equity	$28.82M	$19.23M	$23.96M
YoY Change	49.86%	-29.79%	-38.91%

Cashflow Statement

Concept	2019 Q2	2018 Q2	2018 Q1
OPERATING ACTIVITIES
Net Income	-$4.651M	-$5.799M	-$10.28M
YoY Change	-19.8%	-54.7%	-32.98%
Depreciation, Depletion And Amortization	$230.0K	$240.0K	$277.0K
YoY Change	-4.17%	-42.86%	-35.58%
Cash From Operating Activities	-$3.620M	-$4.470M	-$6.877M
YoY Change	-19.02%	-50.61%	-48.14%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	-$130.0K
YoY Change	-92.31%	550.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00		$50.00K
YoY Change
Cash From Investing Activities	$0.00	-$180.0K	$46.00K
YoY Change	-100.0%	800.0%	-253.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.670M	370.0K	15.86M
YoY Change	351.35%	-3800.0%	6795.65%
NET CHANGE
Cash From Operating Activities	-3.620M	-4.470M	-6.877M
Cash From Investing Activities	0.000	-180.0K	46.00K
Cash From Financing Activities	1.670M	370.0K	15.86M
Net Change In Cash	-1.950M	-4.280M	9.029M
YoY Change	-54.44%	-52.86%	-169.13%
FREE CASH FLOW
Cash From Operating Activities	-$3.620M	-$4.470M	-$6.877M
Capital Expenditures	-$10.00K	-$130.0K
Free Cash Flow	-$3.610M	-$4.340M	-$6.877M
YoY Change	-16.82%	-51.94%	-48.02%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	avgr	Product Warranty Accrual Payments And Release ProductWarrantyAccrualPaymentsAndRelease	93000
	avgr	Proceeds From The Issuance Of Common Stock Under Officers And Directors Purchase Plan ProceedsFromTheIssuanceOfCommonStockUnderOfficersAndDirectorsPurchasePlan	36000
	avgr	Accretion Of Preferred Stock Dividends AccretionOfPreferredStockDividends	1790000
	avgr	Accretion Of Preferred Stock Dividends AccretionOfPreferredStockDividends	1246000
CY2015Q3	avgr	Debt Instrument Covenant Compliance Cash And Certain Cash Equivalents Minimum DebtInstrumentCovenantComplianceCashAndCertainCashEquivalentsMinimum	5000000
CY2018Q1	avgr	Debt Instrument Covenant Compliance Cash And Certain Cash Equivalents Minimum DebtInstrumentCovenantComplianceCashAndCertainCashEquivalentsMinimum	3500000
CY2015Q3	avgr	Debt Instrument Covenant Compliance Prepayment Multiplier For Revenue Shortfall DebtInstrumentCovenantCompliancePrepaymentMultiplierForRevenueShortfall	2
	avgr	Proceeds From The Issuance Of Common Stock Under Officers And Directors Purchase Plan ProceedsFromTheIssuanceOfCommonStockUnderOfficersAndDirectorsPurchasePlan
CY2015Q3	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue After Year Five DebtInstrumentCovenantComplianceTargetMinimumRevenueAfterYearFive	70000000
CY2018Q1	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Eighth Year DebtInstrumentCovenantComplianceTargetMinimumRevenueEighthYear	25000000
CY2015Q3	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Fifth Year DebtInstrumentCovenantComplianceTargetMinimumRevenueFifthYear	60000000
CY2015Q3	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue First Year DebtInstrumentCovenantComplianceTargetMinimumRevenueFirstYear	7000000
CY2015Q3	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Fourth Year DebtInstrumentCovenantComplianceTargetMinimumRevenueFourthYear	50000000
CY2016Q4	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Second Year DebtInstrumentCovenantComplianceTargetMinimumRevenueSecondYear	18000000
CY2015Q3	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Second Year DebtInstrumentCovenantComplianceTargetMinimumRevenueSecondYear	23000000
CY2018Q1	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Seventh Year DebtInstrumentCovenantComplianceTargetMinimumRevenueSeventhYear	20000000
CY2018Q1	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Sixth Year DebtInstrumentCovenantComplianceTargetMinimumRevenueSixthYear	15000000
CY2015Q3	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Third Year DebtInstrumentCovenantComplianceTargetMinimumRevenueThirdYear	40000000
CY2015Q3	avgr	Debt Instrument Final Facility Fee Percentage DebtInstrumentFinalFacilityFeePercentage	0.07
CY2018Q1	avgr	Debt Instrument Final Facility Fee Percentage DebtInstrumentFinalFacilityFeePercentage	0.15
CY2015Q3	avgr	Debt Instrument Financing Fee Percentage DebtInstrumentFinancingFeePercentage	0.015
CY2015Q3	avgr	Debt Instrument Redemption Annual Decline In Prepayment Premium Percentage DebtInstrumentRedemptionAnnualDeclineInPrepaymentPremiumPercentage	0.01
CY2015Q3	avgr	Debt Instrument Redemption Initial Prepayment Premium Percentage DebtInstrumentRedemptionInitialPrepaymentPremiumPercentage	0.05
CY2015Q3	avgr	Debt Instrument Redemption Prepayment Premium Percentage After Fifth Year DebtInstrumentRedemptionPrepaymentPremiumPercentageAfterFifthYear	0
	avgr	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-492000
	avgr	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability
	avgr	Increase Decrease In Other Long Term Liabilities And Accrued Interest IncreaseDecreaseInOtherLongTermLiabilitiesAndAccruedInterest	-30000
	avgr	Increase Decrease In Other Long Term Liabilities And Accrued Interest IncreaseDecreaseInOtherLongTermLiabilitiesAndAccruedInterest	-114000
	avgr	Noncash Interest Expense Income And Other Charges Net NoncashInterestExpenseIncomeAndOtherChargesNet	724000
	avgr	Noncash Interest Expense Income And Other Charges Net NoncashInterestExpenseIncomeAndOtherChargesNet	5037000
	avgr	Operating Lease Rightofuse Asset Amortization OperatingLeaseRightofuseAssetAmortization	219000
	avgr	Operating Lease Rightofuse Asset Amortization OperatingLeaseRightofuseAssetAmortization
	avgr	Payment Of Accrued Interest PaymentOfAccruedInterest
	avgr	Payment Of Accrued Interest PaymentOfAccruedInterest	60000
	avgr	Preferred Stock Deemed Dividend Arising From Beneficial Conversion Feature PreferredStockDeemedDividendArisingFromBeneficialConversionFeature
	avgr	Preferred Stock Deemed Dividend Arising From Beneficial Conversion Feature PreferredStockDeemedDividendArisingFromBeneficialConversionFeature	5216000
CY2019Q2	avgr	Preferred Stock Deemed Dividend Arising From Beneficial Conversion Feature PreferredStockDeemedDividendArisingFromBeneficialConversionFeature
CY2018Q2	avgr	Preferred Stock Deemed Dividend Arising From Beneficial Conversion Feature PreferredStockDeemedDividendArisingFromBeneficialConversionFeature
	avgr	Proceeds From Issuance Of Convertible Preferred Stock Net Of Issuance Costs ProceedsFromIssuanceOfConvertiblePreferredStockNetOfIssuanceCosts
	avgr	Proceeds From Issuance Of Convertible Preferred Stock Net Of Issuance Costs ProceedsFromIssuanceOfConvertiblePreferredStockNetOfIssuanceCosts	15534000
CY2018Q4	avgr	Proceeds From Issuance Or Sale Of Equity Net ProceedsFromIssuanceOrSaleOfEquityNet	10200000
CY2018Q1	avgr	Proceeds From Issuance Or Sale Of Equity Net ProceedsFromIssuanceOrSaleOfEquityNet	15500000
	avgr	Proceeds From Issuance Or Sale Of Equity Net ProceedsFromIssuanceOrSaleOfEquityNet	8000000
CY2018Q3	avgr	Proceeds From Issuance Or Sale Of Equity Net ProceedsFromIssuanceOrSaleOfEquityNet	3000000
	avgr	Proceeds From The Issuance Of Common Stock And Convertible Preferred Stock Net Of Issuance Costs ProceedsFromTheIssuanceOfCommonStockAndConvertiblePreferredStockNetOfIssuanceCosts
	avgr	Proceeds From The Issuance Of Common Stock And Convertible Preferred Stock Net Of Issuance Costs ProceedsFromTheIssuanceOfCommonStockAndConvertiblePreferredStockNetOfIssuanceCosts	326000
	avgr	Reclassification Of Right Of Use Asset To Prepaid Rent ReclassificationOfRightOfUseAssetToPrepaidRent	179000
	avgr	Reclassification Of Right Of Use Asset To Prepaid Rent ReclassificationOfRightOfUseAssetToPrepaidRent
CY2018Q2	avgr	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	581000
CY2019Q2	avgr	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1653000
	avgr	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	581000
	avgr	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	7993000
	avgr	Transfer Between Inventories And Property And Equipment TransferBetweenInventoriesAndPropertyAndEquipment	287000
	avgr	Transfer Between Inventories And Property And Equipment TransferBetweenInventoriesAndPropertyAndEquipment
	avgr	Warranty Period WarrantyPeriod	P1Y
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1086000
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1148000
CY2019Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1210000
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1154000
CY2019Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	776000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1449000
	us-gaap	Interest Paid Net InterestPaidNet	60000
CY2019Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	348505000
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	338342000
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	836000
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	895000
	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	1246000
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10144000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1656000
	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	1790000
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	641000
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	516000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1259000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1009000
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	516000
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	641000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1009000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1260000
CY2019Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	218000
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	260000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	86000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	57000
CY2019Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24185543
CY2018Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18091408
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	36799980
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17794530
CY2019Q2	us-gaap	Assets Assets	28819000
CY2018Q4	us-gaap	Assets Assets	23699000
CY2019Q2	us-gaap	Assets Current AssetsCurrent	20833000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	21621000
CY2019Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	0
CY2018Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	0
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14754000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16410000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5389000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4755000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.16
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-51.82
CY2018Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1797900
CY2019Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	27593789
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	47575393
CY2019Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6421317
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3492200
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6421317
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3492200
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	6000
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	3000
CY2019Q2	us-gaap	Cost Of Revenue CostOfRevenue	1599000
CY2018Q2	us-gaap	Cost Of Revenue CostOfRevenue	2169000
	us-gaap	Cost Of Revenue CostOfRevenue	3066000
	us-gaap	Cost Of Revenue CostOfRevenue	3584000
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	38000000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	428000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	518000
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.87
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-9.83
CY2019Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1439000
CY2019Q2	us-gaap	Dividends Payable Current DividendsPayableCurrent	1790000
CY2018Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	2918000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2383000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	242000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	334000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1066000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-575000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-104000
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1197000
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2019Q2	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2018Q2	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2019Q2	us-gaap	Gross Profit GrossProfit	720000
CY2018Q2	us-gaap	Gross Profit GrossProfit	-111000
	us-gaap	Gross Profit GrossProfit	1093000
	us-gaap	Gross Profit GrossProfit	283000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-62000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-301000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	56000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	593000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-673000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	334000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	439000
CY2019Q2	us-gaap	Interest Expense InterestExpense	364000
CY2018Q2	us-gaap	Interest Expense InterestExpense	362000
	us-gaap	Interest Expense InterestExpense	714000
	us-gaap	Interest Expense InterestExpense	5034000
	us-gaap	Interest Paid Net InterestPaidNet
CY2019Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1721000
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1162000
CY2019Q2	us-gaap	Inventory Net InventoryNet	4105000
CY2018Q4	us-gaap	Inventory Net InventoryNet	3422000
CY2019Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1689000
CY2018Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2102000
CY2019Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	695000
CY2018Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	158000
	us-gaap	Inventory Write Down InventoryWriteDown	97000
	us-gaap	Inventory Write Down InventoryWriteDown	528000
CY2019Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	90000
CY2018Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	50000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	172000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	83000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	106000
CY2019Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.065
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5800000
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6623000
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1138000
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1203000
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1162000
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1123000
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1085000
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	912000
CY2019Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1027000
CY2019Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2019Q2	us-gaap	Liabilities Liabilities	18899000
CY2018Q4	us-gaap	Liabilities Liabilities	14239000
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28819000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23699000
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	14355000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14198000
CY2015Q3	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	50000000
	us-gaap	Nature Of Operations NatureOfOperations	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div> Organization</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Organization, Nature of Business</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">Avinger, Inc. (the “Company”), a Delaware corporation, was incorporated in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2007.</div> The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (“PAD”). Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. The Company manufactures and sells a suite of products in the United States (“U.S.”) and in select international markets. The Company has developed its Lumivascular platform, which integrates optical coherence tomography (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> “OCT”) </div>visualization with interventional catheters and is the industry’s only system that provides real-time intravascular imaging during the treatment portion of PAD procedures. The Company’s Lumivascular platform consists of a capital component, Lightbox, as well as a variety of disposable catheter products. The Company’s current products include its non-imaging catheters, Wildcat and Kittycat, as well as its Lumivascular platform products, Ocelot, Ocelot PIXL and Ocelot MVRX, all of which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (“CTO”). In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company received <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">510</div>(k) clearance from the U.S. Food and Drug Administration (“FDA”) for commercialization of Pantheris, the Company’s image-guided atherectomy system, designed to allow physicians to precisely remove arterial plaque in PAD patients. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2018, </div>the Company also received <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">510</div>(K) clearance from the FDA for its next-generation of Pantheris. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2019, </div>the Company further received FDA clearance for Pantheris SV, a lower profile Pantheris. The Company has sales in the U.S. and select international markets. The Company is located in Redwood City, California.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Liquidity Matters</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic;">Presentation of Financial Statements - Going Concern (Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">205</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div>) </div>requires the Company to make certain disclosures if it concludes that there is substantial doubt about the entity’s ability to continue as a going concern within <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year from the date of the issuance of these financial statements.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019, </div>the Company had an accumulated deficit of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$338.6</div> million. The Company expects to incur losses for the foreseeable future. The Company believes that its cash and cash equivalents of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$14.8</div> million at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> and expected revenues and funds from operations will be sufficient to allow the Company to fund its current operations through at least the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">fourth</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019.</div> Even though we received net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.2</div> million from the sale of our Series C Preferred Stock and common stock in our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2018 </div>offering, net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15.5</div> million from the sale of our Series B preferred stock and warrants in our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2018 </div>offering, proceeds from issuance of common stock upon the exercise of warrants in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$8.0</div> million and net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.0</div> million from the sale of common stock and warrants in our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2018 </div>offering, the Company will need to raise additional funds through future equity or debt financings within the next <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months to meet its operational needs and capital requirements for product development, clinical trials and commercialization and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>subsequently require additional fundraising. The Company can provide <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assurance that it will be successful in raising funds pursuant to additional equity or debt financings or that such funds will be raised at prices that do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> create substantial dilution for our existing stockholders. Given the recent decline in the Company’s stock price, any financing that we undertake in the next <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months could cause substantial dilution to our existing stockholders, there can be <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable to it, the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>have to significantly reduce its operations or delay, scale back or discontinue the development of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> or more of its products. The financial statements do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include any adjustments that might result from the outcome of this uncertainty. The Company’s ultimate success will largely depend on its continued development of innovative medical technologies, its ability to successfully commercialize its products and its ability to raise significant additional funding.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">Additionally, due to the substantial doubt about the Company’s ability to continue operating as a going concern and the material adverse change clause in the Loan Agreement with CRG, the entire amount of borrowings at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> has been classified as current in these financial statements. CRG has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> invoked the material adverse change clause.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:left;text-indent:36pt;"> </div><div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Public Offerings</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 14.7pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> we completed a public offering of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,979</div> shares of Series B preferred stock and warrants to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,797,900</div> shares of common stock. As a result, we received net proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15.5</div> million after underwriting discounts, commissions, legal and accounting fees. The Series B preferred stock has a liquidation preference of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.001</div> per share, full ratchet price based anti-dilution protection, has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> voting rights and is subject to certain ownership limitations. The Series B preferred stock is immediately convertible at the option of the holder, has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> stated maturity, and does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> pay regularly stated dividends or interest. Each share of Series B preferred stock is accompanied by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> Series <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> warrant that expires on the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seventh</div> anniversary of the date of issuance to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50</div> shares of common stock and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> Series <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> warrant that expires on the earlier of (i) the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seventh</div> anniversary of the date of issuance or (ii) the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60th</div> calendar day following the receipt and announcement of FDA clearance of our Pantheris below-the-knee device (or the same or similar product with a different name) to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50</div> shares of common stock; provided, however, if at any time during such <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div>-day period the volume weighted average price for any trading day is less than the then effective exercise price, the termination date shall be extended to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seven</div> year anniversary of the initial exercise date. In addition, pursuant to the Series A Purchase Agreement, we issued to CRG <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,800</div> shares of Series A preferred stock at the closing of the Series B Offering. The Series A preferred stock was issued in exchange for the conversion of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$38.0</div> million of the outstanding principal amount of their senior secured term loan (plus the back-end fee and prepayment premium applicable thereto), totaling approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$41.8</div> million. The Series A Preferred Stock is initially convertible into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,090,000</div> shares of common stock subject to certain limitations contained in the Series A Purchase Agreement.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> we entered into a securities purchase agreement with certain investors pursuant to which we agreed to sell and issue, in a registered direct offering, an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">216,618</div> shares of our common stock at an offering price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$16.425</div> per share. In a concurrent private placement, or the Private Placement, we agreed to issue to these investors warrants exercisable for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> share of our common stock for each <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> shares purchased in the registered direct offering, which equals an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">108,309</div> shares of common stock. The closing of such registered direct offering and the concurrent Private Placement occurred on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> in connection with which we received net proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.0</div> million after deducting placement agent fees and other expenses payable by us and the conversion price of the outstanding shares of Series B preferred stock, issued in our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2018 </div>offering, was reduced to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.58</div> per share as a result. The warrants have an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15.80</div> per share of our common stock and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be exercised from time to time beginning on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> and expire on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2021.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 1, 2018, </div>we completed a public offering of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">728,500</div><div style="display: inline; text-decoration: underline;"> </div>shares of common stock and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,586</div> shares of Series C convertible preferred stock (the “Series C preferred stock”). As a result, we received net proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.2</div> million after underwriting discounts, commissions, legal and accounting fees. Upon any dissolution, liquidation or winding up, whether voluntary or involuntary, holders of Series C preferred stock will be entitled to receive distributions out of our assets, whether capital or surplus, of an amount equal to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.001</div> per share of Series C preferred stock before any distributions shall be made on the common stock but after distributions shall be made on any outstanding Series A preferred stock and any of our existing or future indebtedness. The Series C preferred stock has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> voting rights.</div></div>
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8029000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16226000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-70000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-125000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11346000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-4651000
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	45671
CY2019Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2019Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	764000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	635000
CY2019Q2	us-gaap	Prepaid Rent PrepaidRent	179000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9615000
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-5799000
	us-gaap	Net Income Loss NetIncomeLoss	-9706000
	us-gaap	Net Income Loss NetIncomeLoss	-16080000
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5546000
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6635000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11496000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22542000
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	5426000
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	5603000
	us-gaap	Operating Expenses OperatingExpenses	10826000
	us-gaap	Operating Expenses OperatingExpenses	11880000
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4706000
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5714000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9733000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11597000
CY2019Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	314000
CY2018Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	480000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	806000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	960000
CY2019Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	6000000
CY2019Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	5596000
CY2019Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1063000
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent
CY2019Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4533000
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6000000
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5596000
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	384000
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent
CY2019Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	11000
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	41000
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	329000
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	227000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	569000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	468000
	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts
	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts	155000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	88000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	125000
CY2019Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	895000
CY2018Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	836000
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1790000
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1246000
CY2019Q2	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	46535000
CY2018Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	44718000
CY2019Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2019Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	44923
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	45671
CY2019Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	44923
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	18000
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7993000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	581000
CY2018Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	272000
CY2019Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	215000
	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	36000
	us-gaap	Profit Loss ProfitLoss	-9706000
	us-gaap	Profit Loss ProfitLoss	-16080000
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2006000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2078000
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	45000
CY2019Q2	us-gaap	Purchase Obligation PurchaseObligation	1900000
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1335000
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1159000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2749000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2936000
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-338591000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-328885000
CY2019Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2319000
CY2018Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2058000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4159000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3867000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4680000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2019Q2	us-gaap	Share Price SharePrice	3.03
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y109D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y255D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y109D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y109D
CY2019Q2	us-gaap	Secured Debt Current SecuredDebtCurrent	8201000
CY2018Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	7486000
CY2019Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4091000
CY2018Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4444000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8077000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8944000
	us-gaap	Share Based Compensation ShareBasedCompensation	1009000
	us-gaap	Share Based Compensation ShareBasedCompensation	1260000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7193000
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1318.21
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	371000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	103000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7954000
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7480000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1707.30
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1340.79
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	7480000
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1340.79
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	2863.83
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1876.54
	us-gaap	Stock Issued1 StockIssued1	2918000
	us-gaap	Stock Issued1 StockIssued1
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2019Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	18000
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	36000
CY2018Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	106000
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	106000
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	337000
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	11903000
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	6592000
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	13279000
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	9920000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-35690000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	9460000
	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its common stock valuation and related stock-based compensation, the valuation of the common stock warrants, the valuation of compound embedded derivatives, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>undertake in the future, actual results <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>ultimately materially differ from these estimates and assumptions.</div></div></div>
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6377000
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	675000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5319000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	435000
CY2018	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	0
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	0

Files In Submission

Name	View Source	Status
0001437749-19-016045-index-headers.html	Edgar Link	pending
0001437749-19-016045-index.html	Edgar Link	pending
0001437749-19-016045.txt	Edgar Link	pending
0001437749-19-016045-xbrl.zip	Edgar Link	pending
avgr-20190630.xml	Edgar Link	completed
avgr-20190630.xsd	Edgar Link	pending
avgr-20190630_cal.xml	Edgar Link	unprocessable
avgr-20190630_def.xml	Edgar Link	unprocessable
avgr-20190630_lab.xml	Edgar Link	unprocessable
avgr-20190630_pre.xml	Edgar Link	unprocessable
avgr20190630_10q.htm	Edgar Link	pending
ex_151830.htm	Edgar Link	pending
ex_151831.htm	Edgar Link	pending
ex_151832.htm	Edgar Link	pending
ex_153948.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVGR
Avinger Inc Stock $avgr

2019 Q2 Form 10-Q Financial Statement

#000143774919016045 Filed on August 08, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVGR Avinger Inc Stock $avgr

2019 Q2 Form 10-Q Financial Statement

#000143774919016045 Filed on August 08, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVGR
Avinger Inc Stock $avgr